Evidence map›Paper›PMID 23497174›Full record

ArticleJournal of inflammation (London, England)2013

Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma.

Ida Silvestri, Susanna Cattarino, AnnaMaria Aglianò, Chiara Nicolazzo, Susanna Scarpa, Stefano Salciccia, Luigi Frati, Vincenzo Gentile, Alessandro Sciarra

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 32 citations in OpenAlex.

  1. Synergism of Specific Maca Phenotypes (Molecules (Basel, Switzerland) · 2024
    Article
  2. Review
  3. Article
  4. Review
  5. International journal of molecular sciences · 2020
    Article
  6. Use of saw palmetto (Food science and biotechnology · 2019
    Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ida SilvestriDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Susanna CattarinoDepartment of Urology, Sapienza University of Rome, Rome, Italy.
AnnaMaria AglianòDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Chiara NicolazzoDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Susanna ScarpaDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Stefano SalcicciaDepartment of Urology, Sapienza University of Rome, Rome, Italy.
Luigi FratiDepartment of Experimental Medicine and Pathology, Sapienza University of Rome, Rome, Italy.
Vincenzo GentileDepartment of Urology, Sapienza University of Rome, Rome, Italy.
Alessandro SciarraDepartment of Urology, Sapienza University of Rome, Rome, Italy ; Prostate Unit - Department Urology, University Sapienza, Viale Policlinico 155, 00161, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo analyze the expression at basal level of inflammation-related cytokines and chemokines and the activation status of the NF-κB pathway, together with the proliferation and apoptosis indexes in two widely used in vitro tumor models, the androgen-dependent human Prostate Cancer (PC) cell line LNCaP and the androgen-independent PC3 , and in primary cultures of human PC cells. To assess in these models and primary cultures, the effects of Serenoa repens (LSESr, Permixon®) on proliferation/apoptosis ratio, inflammation-related genes expression and NF-κB pathway activation.

methodsThe expression of IL-6, CCL-5, CCL-2, COX-1, COX-2, iNOS inflammation-related genes has been evaluated at the mRNA level in two in vitro human PC models (LNCaP and PC3 cell lines) and in 40 independent human prostatic primary cultures obtained from PC patients undergoing radical prostatectomy. Tissue fragments were collected from both PC lesions and normal hyperplastic tissue counterparts for each case. All cultures were treated with two different amounts of Permixon® (44 and 88 μg/ml) for different time points (16, 24, 48 and 72 hours), depending on the cell type and the assay; the expression of inflammation-related genes, cell growth (proliferation/apoptosis ratio) and NF-κB activation has been analyzed in treated and untreated cells by means of semi-quantitative RNA-PCR, cell proliferation and immunofluorescence respectively.

resultsWe detected a significant reduction (p <0.001) in PC and normal cells proliferation due to Permixon ® treatment. This result was related to an increase of the apoptotic activity showed by an increase in the number of anti-caspase-3 fluorescent cells. Almost all the inflammation-related genes (IL-6, CCL-5, CCL-2, COX-2 and iNOS) were expressed at the basal level in in vitro cultured cells and primary cultures and down-regulated by Permixon® treatment. This treatment interfered with NF-kB activation, detecting by the translocation of more than 30% of NF-κB p65 subunit to the nucleus.

conclusionsThe present study confirms the expression of inflammatory pattern in PC. We showed the effect of Permixon® on down-regulation of inflammatory-related genes in cell lines and in primary cultures. The inhibitory effect of Permixon® on cell growth could be partly associated to the down-regulation of inflammatory-related genes and to the activation of NF-κB pathway in prostate tissue.

Indexed as

ApoptosisCaspase detectionCell culturesInflammationProliferationProstate neoplasm

Identifiers

PMID23497174
PMCPMC3653817
OpenAlexW2138362250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.